Please describe your practice as a clinician,how many patients with Early Alzheimer’s Disease do you treat on a yearly basis? Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space.

Could you please describe the mechanism of action of Sigma-1 receptor (SIGMAR1) agonists, in detail, and that of SIGMAR1 activation?

What is your overall impression regarding blarcamesine?

Please discuss the key results, where:Randomized, placebo-controlled clinical trial in 132 patients with Parkinson’s disease dementia (PDD) included prespecified biomarkers of response as well as Whole Exome Sequencing DNA data and full RNA exome expression data collection. This study demonstrated dose dependent, statistically significant improvement of dementia assessment, Quality of Episodic Memory with ANAVEX®2-73 (p=0.003) as well as significant improvement of Parkinson’s assessment, MDS-UPDRS Total score (p=0.034) for patients treated with ANAVEX®2-73 high oral dose once daily during 14-week trial • ANAVEX®2-73 transcriptomics analysis (RNAseq), identified a gene network that is differentially expressed in Parkinson’s disease dementia (PDD) patients treated with ANAVEX®2-73 compared to placebo after 14 weeks of treatment • Biological relevance of this gene network was assessed through pathway analysis and confirmed the impact of ANAVEX®2-73 treatment on pathways involved in neurodegenerative diseases, especially Alzheimer’s disease and Parkinson’s disease • While genes are down-regulated in Alzheimer’s disease and Parkinson’s disease, ANAVEX®2-73 singularly impacted expression levels of these genes in multiple pathways by countering the pathological down-regulation of genes in both Alzheimer’s (p<0.005) and Parkinson’s disease (p<0.005) and other degenerative diseases (p<0.005) and these may represent additional potential biomarkers of disease pathology and response